Literature DB >> 27581509

No Benefit for Idarucizumab.

Peter Pommer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27581509      PMCID： PMC5012166          DOI： 10.3238/arztebl.2016.0541a

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  2 in total

1.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

Review 2.  The Periprocedural Management of Anticoagulation and Platelet Aggregation Inhibitors in Endoscopic Interventions.

Authors:  Christian M Lange; Stephan Fichtlscherer; Wolfgang Miesbach; Stefan Zeuzem; Jörg Albert
Journal:  Dtsch Arztebl Int       Date:  2016-02-26       Impact factor: 5.594
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.